Seasoned life sciences investor Dr Eric Shiozaki, DCVC Bio, to headline AusBioInvest 2024, Australia’s premier life sciences investment conference, in Melbourne this October.
Dr Eric Shiozaki, Partner, DCVC Bio, formerly of Novo Ventures, the world-leading life science venture capital firm, has been announced as a keynote speaker.
Dr Shiozaki will deliver an engaging keynote, ‘Investing in innovation at the intersection of technology & biology’ at AusBioInvest in Melbourne on October 29, discussing the emerging applications of technology within the biotech sector.
During this keynote, attendees will gain an understanding of the critical factors for assessing new technologies and their potential commercial application, with a focus on the trends and themes impacting Biotechnology 4.0, before an audience Q&A.
This keynote, and conference, is ideal for both non-specialist investors wanting to dip their toes into biotech investing, as well as seasoned life science investors looking to inform their next investment.
As Partner at DCVC Bio, Dr Shiozaki contributes to strategic decision-making and business development, and is focused on identifying disruptive technologies in healthcare, particularly in drug development and medical technologies. He collaborates closely with entrepreneurs to build companies aimed at advancing medicine and promoting human health.
Dr Shiozaki holds diverse experience in both public and private investments. Prior to joining DCVC, Dr Shiozaki was a Partner at Novo Ventures where he managed the firm’s public equities strategy for SMIDcap and late-stage biotech and medtech companies. His earlier roles include Director at Apposite Capital and Associate at Burrill & Company. Trained as a structural biologist, Dr Shiozaki was a Leukemia & Lymphoma Society Post-Doctoral Fellow.
Dr Shiozaki is the first keynote speaker announced for AusBioInvest 2024, a premier one-day event featuring keynote presentations and panel discussions from local and international life science investment specialists on topics including industry trends and market updates.
AusBioInvest 2024 directly connects the investment community with innovative companies, enabling Australian life science companies to present their business case in an eight-minute pitch to a room full of investors. Its business partnering system and on-site networking lounge offer additional networking opportunities for both investors and companies.
AusBiotech invites qualified investors, including venture capital firms, private equity investors, high-net-worth individuals, research analysts, brokers, family offices, to access their complimentary tickets to attend AusBioInvest 2024, providing them with a valuable opportunity to make meaningful connections with companies, hear the latest market updates, and explore potential investment prospects. Register your interest .
Biotech companies are also being invited to to pitch at AusBioInvest 2024 to a global audience of investors, industry executives, and key stakeholders. Join the investee cohort alongside BiomeBank, Evithé Biotechnology, Immuron Limited (AX:IMC), Invion (ASX:IVX), Nyrada (ASX:NYR), and PharmAust Limited.
Delegates can also .
AusBioInvest 2024 is proudly supported by Host State Partner the Victoria State Government.
